John Sullivan to Antiretroviral Therapy, Highly Active
This is a "connection" page, showing publications John Sullivan has written about Antiretroviral Therapy, Highly Active.
Connection Strength
0.246
-
Greenough TC, Cunningham CK, Muresan P, McManus M, Persaud D, Fenton T, Barker P, Gaur A, Panicali D, Sullivan JL, Luzuriaga K. Safety and immunogenicity of recombinant poxvirus HIV-1 vaccines in young adults on highly active antiretroviral therapy. Vaccine. 2008 Dec 09; 26(52):6883-93.
Score: 0.075
-
Newell ML, Huang S, Fiore S, Thorne C, Mandelbrot L, Sullivan JL, Maupin R, Delke I, Watts DH, Gelber RD, Cunningham CK. Characteristics and management of HIV-1-infected pregnant women enrolled in a randomised trial: differences between Europe and the USA. BMC Infect Dis. 2007 Jun 20; 7:60.
Score: 0.069
-
Luzuriaga K, Sullivan JL. Prevention of mother-to-child transmission of HIV infection. Clin Infect Dis. 2005 Feb 01; 40(3):466-7.
Score: 0.058
-
McManus M, Mick E, Hudson R, Mofenson LM, Sullivan JL, Somasundaran M, Luzuriaga K. Early Combination Antiretroviral Therapy Limits Exposure to HIV-1 Replication and Cell-Associated HIV-1 DNA Levels in Infants. PLoS One. 2016; 11(4):e0154391.
Score: 0.032
-
Dorenbaum A, Cunningham CK, Gelber RD, Culnane M, Mofenson L, Britto P, Rekacewicz C, Newell ML, Delfraissy JF, Cunningham-Schrader B, Mirochnick M, Sullivan JL. Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial. JAMA. 2002 Jul 10; 288(2):189-98.
Score: 0.012